In addition, when assessing the risk of breast and kidney cancer during treatment with canagliflozin, no significant increase in the risk of these cancers was found compared to a group treated with other antidiabetic drugs (insulin, metformin, sulfonylurea, pioglitazone) [70,79]. This evidence concerns the gene INS and cancer.